Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2024

This “Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2024” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Beta Selective Thyroid Hormone Receptor Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Beta Selective Thyroid Hormone Receptor Agonist Understanding

Beta Selective Thyroid Hormone Receptor Agonist: Overview

Thyroid hormones (THs) elicit significant effects on numerous physiological processes, such as growth, development, and metabolism. A lack of thyroid hormones is not compatible with normal health. Most THs effects are mediated by two different thyroid hormone receptor (TR) isoforms, namely TRa and TRß, with the TRß isoform known to be responsible for the main beneficial effects of TH on liver. In brain, despite the crucial role of TRa isoform in neuronal development, TRß has been proposed to play a role in the remyelination processes. TRß is the predominant isoform of TR in the liver and therefore is primarily responsible for the reduction of cholesterol levels, whereas the adverse effects on heart and bone are mainly connected to TRa. Thus, in the development of clinically useful drug candidates, much effort has been directed toward the design of compounds with isomer-specific activity related to the structure of thyroid hormones, i.e., thyromimetics that are liver and/or TRß selective.

Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Beta Selective Thyroid Hormone Receptor Agonist pipeline landscape is provided which includes the disease overview and Beta Selective Thyroid Hormone Receptor Agonist treatment guidelines. The assessment part of the report embraces, in depth Beta Selective Thyroid Hormone Receptor Agonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Beta Selective Thyroid Hormone Receptor Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Beta Selective Thyroid Hormone Receptor Agonist R&D. The therapies under development are focused on novel approaches to treat/improve Beta Selective Thyroid Hormone Receptor Agonist.

Beta Selective Thyroid Hormone Receptor Agonist Emerging Drugs Chapters

This segment of the Beta Selective Thyroid Hormone Receptor Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Beta Selective Thyroid Hormone Receptor Agonist Emerging Drugs

Resmetirom: Madrigal Pharmaceuticals Resmetirom (MGL-3196) is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist. Preclinical, toxicology, Phase I, and Phase II clinical data suggest resmetirom has an attractive, differentiated profile as a potential treatment for non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) and associated dyslipidemias. It is currently in Phase III stage of development.

VK2809: Viking Therapeutics VK2809 is an orally available small molecule agonist of the thyroid hormone receptor that possesses selectivity for liver tissue, as well as the beta receptor subtype, and has demonstrated promising therapeutic potential in a range of lipid disorders, including NASH.

Beta Selective Thyroid Hormone Receptor Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Beta Selective Thyroid Hormone Receptor Agonist drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Beta Selective Thyroid Hormone Receptor Agonist

There are approx. 14+ key companies which are developing the therapies for Beta Selective Thyroid Hormone Receptor Agonist. The companies which have their Beta Selective Thyroid Hormone Receptor Agonist drug candidates in the most advanced stage, i.e. Phase III include, Madrigal Pharmaceuticals.

Phases

This report covers around 14+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Beta Selective Thyroid Hormone Receptor Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Beta Selective Thyroid Hormone Receptor Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Beta Selective Thyroid Hormone Receptor Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Beta Selective Thyroid Hormone Receptor Agonist drugs.

Beta Selective Thyroid Hormone Receptor Agonist Report Insights

• Beta Selective Thyroid Hormone Receptor Agonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Beta Selective Thyroid Hormone Receptor Agonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Beta Selective Thyroid Hormone Receptor Agonist drugs?
• How many Beta Selective Thyroid Hormone Receptor Agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Beta Selective Thyroid Hormone Receptor Agonist?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Beta Selective Thyroid Hormone Receptor Agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Beta Selective Thyroid Hormone Receptor Agonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Madrigal Pharmaceuticals
• Ascletis
• Eccogene
• Viking Therapeutics
• Aligos Therapeutics
• Autobahn Therapeutics
• Terns Pharmaceuticals
• Viking Therapeutics

Key Products

• Resmetirom
• ASC-41

Research programme: thyroid hormone receptor beta agonists- VK2809

• ALG-055009
• ABX-002
• TERN-501
• VK 0214

This product will be delivered within 1-3 business days.